Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multi-stage intraputaminal AB-1005 (AAV2-GDNF) gene therapy delivery optimization in Parkinson's disease
2025-522441-21-00Phase 2Authorised
- Sponsor
- AskBio
- Start
- Apr 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ametefgene parvec in Parkinson's disease (PD), sponsored by AskBio. Primary endpoint: Incidence and severity of adverse events. Planned start Apr 2026; status: authorised.
02
Drugs
ametefgene parvec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-522441-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522441-21-00.